Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.

Autor: Ribera JM; Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute (IJC), Institut Germans Trias i Pujol (IGTP) Universitat Autònoma de Barcelona Badalona Spain., Morgades M; Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute (IJC), Institut Germans Trias i Pujol (IGTP) Universitat Autònoma de Barcelona Badalona Spain., Ribera J; Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute (IJC), Institut Germans Trias i Pujol (IGTP) Universitat Autònoma de Barcelona Badalona Spain., Montesinos P; Department of Hematology Hospital Universitari i Politècnic La Fe Valencia Spain., Cano-Ferri I; Department of Hematology Hospital Universitari i Politècnic La Fe Valencia Spain., Martínez P; Department of Hematology Hospital Doce de Octubre Madrid Spain., Esteve J; Department of Hematology Hospital Clínic Barcelona Spain., Esteban D; Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute (IJC), Institut Germans Trias i Pujol (IGTP) Universitat Autònoma de Barcelona Badalona Spain., García-Fortes M; Department of Hematology Hospital Universitario Virgen de la Victoria Málaga Spain., Alonso N; Department of Hematology Complejo Hospitalario Universitario Santiago de Compostela Santiago de Compostela Spain., González-Campos J; Department of Hematology Hospital Universitario Virgen del Rocío. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/CIBERONC. Universidad de Sevilla Sevilla Spain., Bermúdez A; Department of Hematology Hospital Universitario Marqués de Valdecilla Santander Spain., Torrent A; Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute (IJC), Institut Germans Trias i Pujol (IGTP) Universitat Autònoma de Barcelona Badalona Spain., Genescà E; Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute (IJC), Institut Germans Trias i Pujol (IGTP) Universitat Autònoma de Barcelona Badalona Spain., Maluquer C; Department of Hematology, ICO-Hospital Duran i Reynals Hospitalet de Llobregat Spain., Martínez-López J; Department of Hematology Hospital Doce de Octubre Madrid Spain., García-Sanz R; Department of Hematology, Hospital Universitario de Salamanca (HUS/IBSAL) CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC) Salamanca Spain.
Jazyk: angličtina
Zdroj: HemaSphere [Hemasphere] 2024 Apr 02; Vol. 8 (4), pp. e67. Date of Electronic Publication: 2024 Apr 02 (Print Publication: 2024).
DOI: 10.1002/hem3.67
Abstrakt: Competing Interests: Josep‐Maria Ribera has received honoraria and travel grants from Incyte, Novartis, Takeda, AMGEN, and Pfizer. The rest of the authors have no conflict of interest.
Databáze: MEDLINE